Company: INDP
Filing Date: 2025-09-02
Form Type: S-1
Source: 0001493152-25-012531
Chunk: 21

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-09-02
Form: S-1
Chunk 21
---
6,160 |   |     | $                                  |  10,490 |   |
| Stockholders’ equity:                                                                        |     |                      |         |   |     |                        |         |   |     |                                    |         |   |
| Common stock: $0.01 par value, 200,000,000 shares authorized; issued and outstanding 604,963 
 shares (actual), 1,297,324 (pro forma) and 2,078,574 (pro forma as adjusted)                 |     |                      |       6 |   |     |                        |      13 |   |     |                                    |      21 |   |
| Additional paid in capital                                                                   |     |                      |  68,521 |   |     |                        |  75,019 |   |     |                                    |  79,341 |   |
| Accumulated deficit                                                                          |     |                      | (70,200 | ) |     |                        | (70,200 | ) |     |                                    | (70,200 | ) |
| Total stockholders’ equity (deficit)                                                         |     | $                    |  (1,673 | ) |     |                        |   4,832 |   |     |                                    |   9,162 |   |

Each $0.10 increase (decrease) in an assumed combined public offering price of $6.40 per share and accompanying common warrants would increase (decrease) the amount of cash and cash equivalents and total stockholders’ equity by $0.07 million, assuming that the number of shares and accompanying common warrants offered by us, as set forth on the cover page of this prospectus remains the same and after deducting the Placement Agent’s fees and estimated offering expenses payable by us. We may also increase or decrease the number of shares and accompanying common warrants we are offering. An increase (decrease) of 100,000 in the number of shares we are offering would increase (decrease) the amount of cash and cash equivalents and total stockholders’ equity by $0.6 million, after deducting the estimated Placement Agent’s fees and estimated offering expenses payable by us, assuming the assumed combined public offering price stays the same. The information discussed above is illustrative only and will adjust based on the actual combined public offering price, the actual number of shares that we offer in this offering, and other terms of this offering determined at pricing.

The above discussion and table are based on 604,